The Royal Adelaide Hospital will initiate a clinical trial in 2020 focusing on a new cancer treatment that could dramatically raise survival rates for patients with ovarian and lung cancer. The investigational technology utilizes antibodies to carry radiation directly to the targeted cancer cells.
The Clinical Investigative Site
The Royal Adelaide Hospital (RAH) will recruit patients starting in 2020 in partnership with AusHealth, an Australian operation supporting medical research organizations. RAH hopes that the new treatment will improve survival rates for sufferers of lung and ovarian cancer starting first in South Australia, reports the Daily Mail.
Low Dose Radiation Carrier
During the study, investigators will exploit antibodies that will transport a payload of low dose radiation and to target a specific protein that is produced by dying or dead cancer cells reports RAH Cancer Clinical Trials Unit chief Michael Brown. Brown believes that this antibody technology could transform how solid cancers are fought.
In a high tech command center, investigators can scan the radiation signal hence track the patients that have received chemotherapy just how well the chemotherapy is doing at killing the cancer cells. Ultimately, Dr. Brown noted, “Our trial aims to test how well the antibodies can target specific cancer cells to deliver low-dose radiation.”
A Decade in the Making
Drug discovery and development takes a long time. For example, this early stage antibody has been in development for a decade already. But the good news is that not only might it work in ovarian and lung cancer, but it may also transfer to other cancer fights.
Call to Action: TrialSite News has quite a number of readers from Australia. If this is a topic of interest, consider connecting with RAH and Professor Michael Brown. We can make an introduction.Source: Daily Mail